Agitation in Delirium Management Market, by Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies,

Agitation in Delirium Management Market, by Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Delirium is a neurological condition which leads to disturbances in the mental abilities of a person. It causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as old age, exposure to certain medications, alcohol abuse, surgery or other medical procedures and factors such as exposure to toxic or infectious agents, physical trauma, diet, and other behavioral and occupational factors. There are two types of delirium: Hyperactive delirium and Hypoactive delirium. In hyperactive delirium, patients become overactive (agitation in delirium). Currently, market players are carrying out research and development activities for evaluating new medicines for the management of agitation in delirium among the patients.
Market Dynamics

Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients. For instance, in 2017, researchers at the University of California, San Diego, reported that sleep deprivation post-surgery causes delirium (confusion) in patients in the intensive care unit (ICU). Thus, they are conducting clinical trials for studying the role of Ramelteon, a medication that mimics the activity of melatonin (hormone which controls the body’s circadian rhythm or sleep – wake cycle) in improving the sleep quality, thus improving sleep quality is expected to help in preventing occurrence of delirium in the patients post open-heart surgery. The study is expected to be completed by December 1, 2021.
Market players are indulged in launching new first-generation antipsychotic drugs for the treatment of delirium, which is expected to spur the growth of the global agitation in delirium management market. For instance, in 2017, Lupin Limited launched Quetiapine Fumarate Extended-Release Tablets (50 mg, 150 mg, 200 mg, 300 mg and 400 mg strengths), after receiving approval from the U.S. Food and Drug Administration (U.S. FDA).
Key features of the study:
This report provides an in-depth analysis of global agitation in delirium management market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global agitation in delirium management market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis International AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., and BioXcel Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the agitation in delirium management market
Detailed Segmentation:
Global Agitation in Delirium Management Market, By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
Global Agitation in Delirium Management Market, By Route of Administration:
Oral
Intramuscular
Others
Global Agitation in Delirium Management Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Agitation in Delirium Management Market, By Region:
North America
By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
By Route of Administration:
Oral
Intramuscular
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
By Route of Administration:
Oral
Intramuscular
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
By Route of Administration:
Oral
Intramuscular
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
By Route of Administration:
Oral
Intramuscular
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
By Route of Administration:
Oral
Intramuscular
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
Others
By Route of Administration:
Oral
Intramuscular
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Sun Pharmaceutical Industries Ltd.
Glenmark Pharmaceuticals Limited
Mylan N.V.
Fresenius Kabi AG
Novartis International AG
Akorn Incorporated
Zydus Cadila
Pfizer, Inc.
BioXcel Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.